ADT with injectable gonadotropin-releasing hormone (GnRH) receptor agonists such as leuprolide has been associated with cardiovascular morbidity, and cardiovascular disease is the leading cause of ...

PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

Results from Blue Earth Diagnostics’ head-to-head study have been published in the European Journal of Nuclear Medicine and Molecular Imaging and were just presented at the 2026 ASCO Genitourinary ...

TD Cowen 46th Annual Health Care Conference March 4, 2026 9:50 AM ESTCompany ParticipantsMartin Hogan - Senior Director ...

AbCellera Biologics Inc. (NASDAQ: ABCL) Q4 2025 Earnings Call Transcript February 24, 2026 AbCellera Biologics Inc. beats ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

ADT-associated cardiovascular risk may be partly mediated by accelerated coronary atherosclerosis. Plaque progression is more pronounced with the GnRH agonist leuprolide compared with the GnRH ...

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

PSMA-617 to androgen deprivation therapy (ADT) with androgen receptor pathway inhibitor (ARPI) bettered disease control in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according ...

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.